Simplex Trading
OVID icon

Simplex Trading’s Ovid Therapeutics OVID Stock Holding History

Simplex Trading’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$666 Sell
300
-6,800
-96% -$12.2K ﹤0.01% 8682
2025
Q4 		$11.6K Sell
7,100
-147,100
-95% -$227K ﹤0.01% 6898
2025
Q3 		$200K Buy
+154,200
New +$134K ﹤0.01% 4935
2024
Q4 		– Sell
-10,900
Closed -$12K – 9334
2024
Q3 		$12K Sell
10,900
-100
-0.9% -$104 ﹤0.01% 7080
2024
Q2 		$8K Buy
+11,000
New +$30.6K ﹤0.01% 7601
2023
Q3 		– Sell
-1,500
Closed -$4K – 9515
2023
Q2 		$4K Hold
1,500
– – ﹤0.01% 8074
2023
Q1 		$3K Buy
+1,500
New +$3.56K ﹤0.01% 8333
2021
Q4 		– Sell
-276,600
Closed -$1.09M – 11167
2021
Q3 		$1.09M Hold
276,600
– – ﹤0.01% 2929
2021
Q2 		$1.08M Buy
276,600
+273,667
+9,331% +$1.08M ﹤0.01% 2996
2021
Q1 		$1.18M Buy
2,933
+2,657
+963% +$8.82K ﹤0.01% 2208
2020
Q4 		$63K Buy
276
+230
+500% +$1.07K ﹤0.01% 5929
2020
Q3 		$26K Sell
46
-6
-12% -$40 ﹤0.01% 6187
2020
Q2 		$38K Buy
+52
New +$243 ﹤0.01% 5723

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Simplex Trading's OVID Position: Q1 2026 in Review

Simplex Trading reduced its Ovid Therapeutics (OVID) stake by 88% in Q1 2026, selling an estimated $49.9K and leaving 3,674 shares worth $8.16K. The position accounts for ﹤0.01% of the portfolio, ranked #7524.

Simplex Trading first reported a position in OVID in Q4 2020 and has held it in 11 quarters since. The position peaked at $503K in Q3 2025. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Simplex Trading held 3,674 shares of Ovid Therapeutics worth $8.16K as of Q1 2026.
  • Simplex Trading sold 27,929 Ovid Therapeutics shares in Q1 2026, an estimated $49.9K.
  • Ovid Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #7524 holding.
  • Simplex Trading first reported a position in Ovid Therapeutics in Q4 2020 and has held it in 11 quarters since.
  • Simplex Trading's Ovid Therapeutics position peaked at $503K in Q3 2025.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.